{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:17:09Z","timestamp":1790381829412,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ciltacabtagene autoleucel (cilta\u2010cel) has demonstrated excellent efficacy and long\u2010term disease control in patients with relapsed\/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12\u2009months) in patients with RRMM receiving standard\u2010of\u2010care cilta\u2010cel across the three Mayo clinic centers. Patients with a follow\u2010up of at least 12\u2009months or progression or death within 12\u2009months from infusion were included. Of the patients with early treatment failure (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200952), 69% had progressive disease and 31% had a non\u2010relapse mortality (NRM) event. In patients without early treatment failure (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009164), 13% of events were NRM. Among pretreatment factors, prior BCMA\u2010directed therapy, presence of extramedullary disease and a CAR\u2010HEMATOTOX score of \u2265\u20092 were independent predictors of early progression or death. The utilization of cilta\u2010cel in earlier lines of treatment (1\u20133 vs. 4 or more) demonstrated comparable PFS (12\u2010month PFS 73% vs. 77%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.94). Measurable residual disease positivity in the bone marrow at 3\u2009months (11\/197 patients) identified a small but high\u2010risk group with an increased risk of early treatment failure (OR 5.68;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012). Patients with less than a complete response on a FDG PET\/CT at 3\u2009months also had an increased risk of early treatment failure (OR 11.8;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Our findings may help identify patients at high\u2010risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70425","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:35:18Z","timestamp":1782448518000},"page":"2269-2279","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Treatment Failure in Patients Receiving Ciltacabtagene\u2010Autoleucel for Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth J. C.","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"},{"name":"Australian Centre for Blood Diseases, Monash University  Melbourne Australia"},{"name":"The Alfred Hospital  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-1447","authenticated-orcid":false,"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dooley","sequence":"additional","affiliation":[{"name":"Department of Research Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre De Menezes Silva","family":"Corraes","sequence":"additional","affiliation":[{"name":"Department of Research Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haily","family":"Stephens","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9434-5269","authenticated-orcid":false,"given":"J. Erin","family":"Wiedmeier\u2010Nutor","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5649-6909","authenticated-orcid":false,"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Research Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine Mayo Clinic  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03278-5"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-94"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00653-9"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70070"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015599"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01555-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w"},{"issue":"12","key":"e_1_2_12_20_1","first-page":"3065","article-title":"Extramedullary Disease Is Associated With Severe Toxicities Following B\u2010Cell Maturation Antigen CAR T\u2010Cell Therapy in Multiple Myeloma","volume":"110","author":"Portuguese A. J.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030182"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024590"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0660-0"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016619"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","unstructured":"S.Kumar C. R.Bachier M.Cavo et\u00a0al. \u201cCAMMA 2: A Phase I\/II Trial Evaluating the Efficacy and Safety of Cevostamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) Who Have Triple\u2010Class Refractory Disease and Have Received a Prior Anti\u2010B\u2010Cell Maturation Antigen (BCMA) Agent \u201d(2023) American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01465-x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01441-3"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00820-y"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00785-y"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:19:31Z","timestamp":1785583171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ajh.70425"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70425","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2026-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}